Q3 EPS Forecast for Sana Biotechnology Increased by Analyst

Sana Biotechnology, Inc. (NASDAQ:SANA) – Stock analysts at HC Wainwright boosted their Q3 2024 earnings per share (EPS) estimates for shares of Sana Biotechnology in a report released on Tuesday, November 5th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.09) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.61) EPS.

A number of other brokerages have also recently commented on SANA. Citigroup increased their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday.

Sana Biotechnology Price Performance

NASDAQ SANA opened at $3.41 on Thursday. The stock’s 50 day simple moving average is $4.38 and its 200-day simple moving average is $5.87. Sana Biotechnology has a 1-year low of $2.85 and a 1-year high of $12.00. The company has a market cap of $758.62 million, a PE ratio of -2.97 and a beta of 1.44.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC increased its position in shares of Sana Biotechnology by 14.8% during the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after acquiring an additional 4,210 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after buying an additional 5,090 shares during the last quarter. Arizona State Retirement System raised its holdings in Sana Biotechnology by 36.7% in the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after acquiring an additional 9,940 shares in the last quarter. Blue Trust Inc. boosted its stake in Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after acquiring an additional 12,154 shares during the last quarter. Finally, Algert Global LLC acquired a new position in Sana Biotechnology during the 2nd quarter worth $73,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 31.10% of the stock is currently owned by company insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.